Hydromorphone for cancer pain

Area of Science:

• Oncology
• Pharmacology
• Pain Management

Background:

• Advanced cancer is associated with high prevalence of pain, often worsening as the disease progresses.
• Opioid pharmacotherapy is a primary treatment for cancer pain.
• Hydromorphone is considered as a potential opioid analgesic for cancer pain management.

Purpose of the Study:

• To evaluate the analgesic efficacy of hydromorphone in relieving cancer pain.
• To determine the incidence and severity of adverse events associated with hydromorphone use.
• To compare hydromorphone with placebo, other opioids, or active controls for cancer pain.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs).
• Searched multiple databases including CENTRAL, MEDLINE, and Embase up to November 2020.
• Included RCTs comparing hydromorphone with placebo or other analgesics for adult and pediatric cancer pain; primary outcomes were pain intensity and relief.

Main Results:

• Eight studies (1283 participants) compared hydromorphone with oxycodone, morphine, or fentanyl; no placebo-controlled studies were found.
• No clear evidence of difference in pain intensity or relief between hydromorphone and oxycodone, morphine, or fentanyl.
• Very low-certainty evidence for adverse events like nausea, vomiting, dizziness, and constipation, with no significant differences observed.

Conclusions:

• The evidence regarding the benefits and harms of hydromorphone for cancer pain is highly uncertain.
• Insufficient evidence exists to support or refute hydromorphone's use compared to other analgesics.
• Further research with larger sample sizes and comprehensive data collection is necessary to clarify hydromorphone's role in cancer pain management.